comparemela.com
Home
Live Updates
Patients With High Risk Largeb Cell - Breaking News
Pages:
Latest Breaking News On - Patients with high risk largeb cell - Page 1 : comparemela.com
Long-Term Data for Kite s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.
Foster city
United states
New york
North vancouver
British columbia
Frank neumann
Meaghan smith
Anna padula
Jerome powell
Barbara shecter
Gabriel friedman
Santa monica
Julioc chavez
Joe oconnor
Jacquie ross
Gilead company
ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard-of-Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma
Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.
Jasonr westin
Randomized controlled study
Axicabtagene ciloleucel versus standard of care
First line therapy
Patients with high risk largeb cell
Zuma 23
Zuma 23 study
Axicabtagene ciloleucel
Standard of care largeb cell lymphoma
Largeb cell lymphoma
High risk largeb cell lymphoma
First line treatments high risk largeb cell lymphoma
Zuma 7
Zuma 1
Zuma 12
Axi cel
vimarsana © 2020. All Rights Reserved.